Health & Life Co., Ltd.
Health & Life Co., Ltd. manufactures and sells products for cardiovascular disease, in-vitro diagnostics, and respiratory care worldwide. It offers vibrating mesh nebulizers, blood pressure monitor products, IR thermometers, and hearing aid devices. The company was founded in 1996 and is based in New Taipei City, Taiwan.
Health & Life Co., Ltd. (1781) - Net Assets
Latest net assets as of September 2025: NT$329.43 Million TWD
Based on the latest financial reports, Health & Life Co., Ltd. (1781) has net assets worth NT$329.43 Million TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$656.14 Million) and total liabilities (NT$326.71 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$329.43 Million |
| % of Total Assets | 50.21% |
| Annual Growth Rate | 1.29% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 11.35 |
Health & Life Co., Ltd. - Net Assets Trend (2021–2024)
This chart illustrates how Health & Life Co., Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Health & Life Co., Ltd. (2021–2024)
The table below shows the annual net assets of Health & Life Co., Ltd. from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$393.05 Million | +17.20% |
| 2023-12-31 | NT$335.37 Million | -9.99% |
| 2022-12-31 | NT$372.58 Million | -1.48% |
| 2021-12-31 | NT$378.18 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Health & Life Co., Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2653800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$481.05 Million | 122.39% |
| Total Equity | NT$393.05 Million | 100.00% |
Health & Life Co., Ltd. Competitors by Market Cap
The table below lists competitors of Health & Life Co., Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dish TV India Limited
PINK:DTTVY
|
$12.97 Million |
|
Saga Pure ASA
OL:SAGA
|
$12.98 Million |
|
Voyageur Pharmaceuticals Ltd
PINK:VYYRF
|
$12.98 Million |
|
LMS Co. Ltd
KQ:073110
|
$12.98 Million |
|
Delta Resources Ltd
PINK:DTARF
|
$12.97 Million |
|
BeLive Holdings Ordinary Share
NASDAQ:BLIV
|
$12.96 Million |
|
Medion AG
XETRA:MDN
|
$12.96 Million |
|
Malton Bhd
KLSE:6181
|
$12.96 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Health & Life Co., Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 335,370,000 to 393,051,000, a change of 57,681,000 (17.2%).
- Net income of 24,239,000 contributed positively to equity growth.
- Other factors increased equity by 33,442,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$24.24 Million | +6.17% |
| Other Changes | NT$33.44 Million | +8.51% |
| Total Change | NT$- | 17.20% |
Book Value vs Market Value Analysis
This analysis compares Health & Life Co., Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.49x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | NT$7.98 | NT$12.35 | x |
| 2022-12-31 | NT$7.86 | NT$12.35 | x |
| 2023-12-31 | NT$7.07 | NT$12.35 | x |
| 2024-12-31 | NT$8.29 | NT$12.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Health & Life Co., Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.17%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.43%
- • Asset Turnover: 0.86x
- • Equity Multiplier: 2.08x
- Recent ROE (6.17%) is above the historical average (-6.23%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -16.48% | -7.68% | 1.05x | 2.05x | NT$-100.16 Million |
| 2022 | -4.71% | -2.20% | 1.00x | 2.15x | NT$-54.81 Million |
| 2023 | -9.91% | -5.53% | 0.85x | 2.12x | NT$-66.77 Million |
| 2024 | 6.17% | 3.43% | 0.86x | 2.08x | NT$-15.07 Million |
Industry Comparison
This section compares Health & Life Co., Ltd.'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,374,396,222
- Average return on equity (ROE) among peers: 7.81%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Health & Life Co., Ltd. (1781) | NT$329.43 Million | -16.48% | 0.99x | $12.97 Million |
| Hi-Clearance (1788) | $3.00 Billion | 11.98% | 0.65x | $104.25 Million |
| Radiant Innovation (3373) | $865.89 Million | -3.30% | 0.08x | $18.65 Million |
| Wellell Inc (4106) | $1.31 Billion | 13.81% | 0.24x | $37.12 Million |
| Rossmax International Ltd (4121) | $1.33 Billion | 1.93% | 1.30x | $38.32 Million |
| United Orthopedic (4129) | $1.77 Billion | 7.55% | 0.46x | $300.33 Million |
| Dynamic Medical Technologies (4138) | $1.76 Billion | 11.67% | 0.71x | $39.41 Million |
| Ok Biotech Co Ltd (4155) | $1.30 Billion | 9.66% | 0.71x | $44.61 Million |
| Bioptik Technology (4161) | $717.83 Million | 6.76% | 1.11x | $30.42 Million |
| EPS Bio Technology Corp. (4183) | $309.15 Million | 10.25% | 0.77x | $4.27 Million |